Back to top
more

Aerpio Pharmaceuticals, Inc. (ARPO)

(Delayed Data from NSDQ)

$1.04 USD

1.04
376,415

+0.01 (0.96%)

Updated May 3, 2019 04:13 PM ET

After-Market: $1.05 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

QIAGEN's (QGEN) NeuMoDx Multiplex Test Receives FDA EUA

by Zacks Equity Research

QIAGEN's (QGEN) new NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage test strengthens the company's portfolio in PCR testing, while becoming a crucial diagnostic tool for the flu season and the pandemic.

Aerpio Pharmaceuticals (ARPO) Is in Oversold Territory: What's Next?

by Zacks Equity Research

Aerpio Pharmaceuticals (ARPO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

What Makes Aerpio Pharmaceuticals, Inc. (ARPO) a New Buy Stock

by Zacks Equity Research

Aerpio Pharmaceuticals, Inc. (ARPO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Aerpio (ARPO) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Aerpio (ARPO) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.

Marinus (MRNS) Gets Positive FDA Response for Ganaxolone Study

by Zacks Equity Research

Marinus (MRNS) gets positive FDA response for phase III Marigold study on oral ganaxolone in children and young adults with CDKL5 deficiency disorder that appears sufficient to support the NDA filing.

Horizon (HZNP) Provides Preliminary 2020 Financial Results

by Zacks Equity Research

Horizon (HZNP) provides 2020 preliminary financial results and updates on its key drugs.

Ultragenyx (RARE) Presents Preliminary 2020 Revenues & Guidance

by Zacks Equity Research

Ultragenyx (RARE) provides preliminary 2020 Crysvita revenues and 2021 revenue guidance for the same.

Aerpio Pharmaceuticals (ARPO) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Aerpio Pharmaceuticals (ARPO) has been struggling lately, but the selling pressure may be coming to an end soon.

Aerpio (ARPO) Seeks Strategic Options for Pipeline Programs

by Zacks Equity Research

Aerpio (ARPO) unveils strategic alternatives after it announced top-line results from a phase II study of razuprotafib in glaucoma patients in December.

Ultragenyx (RARE) Surges on Product Approvals, Pipeline Progress

by Zacks Equity Research

Ultragenyx (RARE), which has a strong pipeline, receives a few approvals for its products in 2020.

Arcturus (ARCT) to Develop ARCT-032 for Cystic Fibrosis

by Zacks Equity Research

Arcturus (ARCT) has selected ARCT-032 as a development candidate for Cystic Fibrosis.

Novo Nordisk (NVO) Files for Ozempic's Label Expansion in EU

by Zacks Equity Research

Novo Nordisk (NVO) files for a label expansion of Ozempic in the EU to include a new dose of 2.0 mg.

Apellis' (APLS) Pipeline Candidate Pegcetacoplan Promising

by Zacks Equity Research

Apellis' (APLS) lead pipeline candidate, pegcetacoplan, is a promising one and being developed for several indications.

Bristol Myers' (BMY) CNS Phase III Cancer Study on Opdivo Fails

by Zacks Equity Research

Bristol Myers' (BMY) phase III study on Opdivo in newly diagnosed glioblastoma failed to meet goals.

Roche's (RHHBY) Phesgo Gets EU Nod to Treat Breast Cancer

by Zacks Equity Research

Roche's (RHHBY) fixed-dose combination of Perjeta and Herceptin administered subcutaneously gets approved by the EC for the treatment of early and metastatic HER2-positive breast cancer.

Jazz (JAZZ) Initiates BLA Submission for Leukemia Candidate

by Zacks Equity Research

Jazz (JAZZ) initiates the submission of a BLA to the FDA for the marketing approval of JZP-458 for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma.

ChemoCentryx (CCXI) Reports Positive Top-Line Rare Disease Data

by Zacks Equity Research

ChemoCentryx (CCXI) and Vifor Fresenius Medical Care Renal Pharma report positive top-line data from the study evaluating avacopan for the treatment of C3 Glomerulopathy.

Novo Nordisk (NVO) Files for Semaglutide Label Expansion in EU

by Zacks Equity Research

Novo Nordisk (NVO) files application in Europe for the label expansion of subcutaneous Ozempic (semaglutide) 2.4 mg.

Ultragenyx (RARE), Mereo Ink Deal for Bone Disease Candidate

by Zacks Equity Research

Ultragenyx (RARE) and Mereo BioPharma ink an agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta.

Novartis (NVS) to Acquire Neuroscience Company for Up to $770M

by Zacks Equity Research

Novartis (NVS) to buy neuroscience company, Cadent, for up to $770 million.

Novartis' (NVS) Entresto Gets FDA Panel Nod for Expanded Use

by Zacks Equity Research

Novartis (NVS) gets positive review from the FDA Advisory Committee to support the use of Entresto in the treatment of patients with heart failure with preserved ejection fraction.

Sangamo Therapeutics (SGMO) Catches Eye: Stock Jumps 6.5%

by Zacks Equity Research

Sangamo Therapeutics (SGMO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Roche (RHHBY) Gets FDA Nod for Shorter Infusion Time of Ocrevus

by Zacks Equity Research

The FDA approves Roche's (RHHBY) Ocrevus for two-hour infusion time, dosed twice-yearly to patients with relapsing or primary progressive MS.

Seagen (SGEN) Gets Positive CHMP Opinion for Breast Cancer Drug

by Zacks Equity Research

Seagen (SGEN) gets a positive opinion from the CHMP, recommending the approval of Tukysa for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer.

Bristol Myers (BMY) Gets Positive CHMP Opinion for Inrebic

by Zacks Equity Research

Bristol Myers (BMY) gets positive CHMP opinion for Inrebic for the treatment of adult patients with newly diagnosed and previously treated myelofibrosis.